JenniferEffieAmengualMD

Hematologic Oncology

Associate Professor, Medicine, Columbia University College of Physicians and Surg

Overview of Dr. Amengual

Dr. Jennifer Amengual is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. She received her medical degree from New York Medical College and has been in practice 13 years. She is one of 378 doctors at New York-Presbyterian Hospital and one of 116 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. She has more than 40 publications and over 500 citings.

Office
622 W 168th St
New York, NY 10032
Book by Phone+1(843) 765-4948

Education & Training

NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2007 - 2010
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2004 - 2007
New York Medical CollegeClass of 2004

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2007 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
Completed
Phase 2
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Start of enrollment: 2013 Sep 09
Completed
Phase 1, Phase 2
ACY-1215 for Relapsed/Refractory Lymphoid Malignancies Start of enrollment: 2014 Apr 02
Completed
Phase 1, Phase 2
Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL Start of enrollment: 2018 Sep 01
Withdrawn
Phase 3
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment Start of enrollment: 2023 Sep 26
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

47 citations
The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma.
Enrica Marchi, Kelly Zullo, Jennifer E Amengual, Matko Kalac, Danielle C Bongero
British Journal of Haematology. 2015-10-01
88 citations
Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study.
Owen A. O'Connor, Lorenzo Falchi, Jennifer K. Lue, Enrica Marchi, Cristina Kinahan
Blood. 2019-10-24
104 citations
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission
Daniel J. Landsburg, Marissa K. Falkiewicz, Joseph Maly, Kristie A. Blum, Christina Howlett
Journal of Clinical Oncology. 2017-05-05

Abstracts/Posters

Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT Activators
Jennifer E Amengual, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies
Jennifer E. Amengual, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Development of First-in-Class Histone Acetyltransferase (HAT) Activators for Precision Targeting of Epigenetic Derangements in Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Pipeline Moves: Moderna’s Pandemic Influenza Vaccine Trial CompletesAugust 19th, 2024